Safety and Biomarker Study of PTC-589 in Participants With Parkinson's Disease

Inclusion Criteria: * Hoehn and Yahr stage ≤3.0 * Ambulatory with or without assistance * Sexually active fertile participants and their partners must agree to use medically accepted methods of contraception (such as, hormonal methods, including oral, subcutaneous, and intrauterine; barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the course of the study and for 3 months after the last dose of study treatment. * Willingness and ability to comply with study procedures * If on medications for Parkinson's disease drugs, then medication regimen must be stable for 60 days prior to enrollment * Abstention from use of other investigative or non-approved drugs for the duration of the trial For Idiopathic Participants * A diagnosis of idiopathic Parkinson's disease confirmed by the presence of bradykinesia plus one or both of the following symptoms: rigidity or resting tremor; and with an abnormal DaTscan consistent with a dopaminergic deficit * Age 40 to 75 years * Within 5 years of diagnosis of Parkinson's disease For Genetic Subtype Participants * A confirmed diagnosis of Parkinson's disease plus a genetic diagnosis consistent with Parkinson's disease, specifically PTEN-induced kinase 1 (PINK1), parkin, Leucine-rich repeat kinase 2 (LRRK2) or other mitochondrial genetic subtype * Age 21 to 75 years Exclusion Criteria: * Allergy to PTC-589 or other components of the PTC-589 tablet formulation * Use of antioxidant supplements, sp…